浙江医药
(600216)
| 流通市值：121.02亿 | | | 总市值：122.32亿 |
| 流通股本：9.51亿 | | | 总股本：9.62亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 4,386,186,607.44 | 2,190,864,565.87 | 8,880,602,021.78 | 6,695,297,924.39 |
| 营业总成本 | 3,816,258,302.17 | 1,909,389,936.37 | 7,817,212,979.34 | 5,638,082,321.04 |
| 其他经营收益 | | | | |
| 营业利润 | 626,987,637.27 | 306,353,983.53 | 962,930,093.23 | 1,048,294,343.4 |
| 利润总额 | 619,710,646.6 | 306,451,485.43 | 951,729,488.24 | 1,046,306,587.3 |
| 净利润 | 515,563,144.33 | 258,361,542.94 | 760,239,195 | 866,731,612.94 |
| 每股收益 | | | | |
| 其他综合收益 | -14,630,975.18 | -8,374,276.06 | 17,625,973.28 | 23,198,143.35 |
| 综合收益总额 | 500,932,169.15 | 249,987,266.88 | 777,865,168.28 | 889,929,756.29 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 7,996,263,820.84 | 7,152,920,832.95 | 7,211,294,695.17 | 7,121,017,781.08 |
| 非流动资产: | | | | |
| 非流动资产合计 | 6,851,230,038.95 | 7,025,586,620.56 | 6,879,392,675.79 | 7,014,510,876.68 |
| 资产总计 | 14,847,493,859.79 | 14,178,507,453.51 | 14,090,687,370.96 | 14,135,528,657.76 |
| 流动负债: | | | | |
| 流动负债合计 | 1,948,031,087.41 | 2,111,369,220.33 | 2,439,799,386.79 | 2,553,967,626.42 |
| 非流动负债: | | | | |
| 非流动负债合计 | 795,677,264.37 | 702,016,009.68 | 561,821,059.67 | 370,484,655.66 |
| 负债合计 | 2,743,708,351.78 | 2,813,385,230.01 | 3,001,620,446.46 | 2,924,452,282.08 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 11,660,189,904.32 | 11,240,627,358.74 | 10,943,373,741.03 | 11,054,845,999.67 |
| 股东权益合计 | 12,103,785,508.01 | 11,365,122,223.5 | 11,089,066,924.5 | 11,211,076,375.68 |
| 负债和股东权益合计 | 14,847,493,859.79 | 14,178,507,453.51 | 14,090,687,370.96 | 14,135,528,657.76 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 4,653,249,447.87 | 2,209,582,997.75 | 9,557,435,816.71 | 7,517,127,199.1 |
| 经营活动现金流出小计 | 4,200,999,751.71 | 2,109,567,191.25 | 7,671,667,105.44 | 6,028,461,425.19 |
| 经营活动产生的现金流量净额 | 452,249,696.16 | 100,015,806.5 | 1,885,768,711.27 | 1,488,665,773.91 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,237,850,815.12 | 507,067,300.43 | 2,118,092,288.33 | 1,521,591,183.19 |
| 投资活动现金流出小计 | 1,957,973,274.87 | 893,583,041.5 | 2,490,039,102.61 | 1,764,620,085.63 |
| 投资活动产生的现金流量净额 | -720,122,459.75 | -386,515,741.07 | -371,946,814.28 | -243,028,902.44 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,031,166,466.6 | 341,100,000 | 769,781,200 | 546,577,625.82 |
| 筹资活动现金流出小计 | 516,743,980.93 | 213,763,445.88 | 1,172,643,856.84 | 914,225,923.19 |
| 筹资活动产生的现金流量净额 | 514,422,485.67 | 127,336,554.12 | -402,862,656.84 | -367,648,297.37 |
| 汇率变动对现金及现金等价物的影响 | -48,739,999.02 | -30,817,344.92 | 90,287,386.88 | 55,426,355.68 |
| 现金及现金等价物净增加额 | 197,809,723.06 | -189,980,725.37 | 1,201,246,627.03 | 933,414,929.78 |
| 期末现金及现金等价物余额 | 3,364,641,761.15 | 2,976,851,312.72 | 3,166,832,038.09 | 2,899,000,340.84 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 197,809,723.06 | - | 1,201,246,627.03 | - |
最新报告期：2026-09-08| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 长城证券 | 王彤,肖亚平 | 1.20 | 1.34 | 1.52 | 2026-09-08 |